Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab

NCT01927757 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

90

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision due to slow enrollment

Conditions

Moderate to Severe Rheumatoid Arthritis

Interventions

BIOLOGICAL: Etanercept
DRUG: Methotrexate

Sponsor

Amgen